Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta 2-microglobulin decrease in cerebrospinal fluid from parkinsonian patients.

M Mogi1, M Harada, K Kojima

  • 1Department of Oral Biochemistry, Matsumoto Dental College, Shiojiri, Japan.

Neuroscience Letters
|September 25, 1989
PubMed
Summary

Levels of beta-2 microglobulin (beta 2-MG) in cerebrospinal fluid are significantly lower in Parkinson's disease patients compared to controls. This finding suggests a potential link between immune system changes and neurodegeneration in Parkinson's disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sandwich enzyme immunoassay of dopamine-?-hydroxylase in cerebrospinal fluid from control and parkinsonian patients.

Neurochemistry international·2010
Same author

Preface: Malignant syndrome in Parkinson's disease.

Parkinsonism & related disorders·2003
Same author

[Executive function in Parkinson's disease].

Rinsho shinkeigaku = Clinical neurology·2001
Same author

Neuropsychological outcome following pallidotomy and thalamotomy for Parkinson's disease.

Stereotactic and functional neurosurgery·2000
Same author

[Clinical pathophysiology of parkinsonian symptoms: from experiences of stereotaxic surgery].

Nihon rinsho. Japanese journal of clinical medicine·2000
Same author

Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease.

Clinical neuropharmacology·2000

Area of Science:

  • Neuroimmunology
  • Biochemistry

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder primarily affecting dopaminergic neurons.
  • Previous research indicated decreased dopamine beta-hydroxylase (DBH) activity in the cerebrospinal fluid (CSF) of PD patients.

Purpose of the Study:

  • To establish and validate a sandwich enzyme immunoassay (EIA) for measuring beta-2 microglobulin (beta 2-MG) levels in human CSF.
  • To investigate the association between beta 2-MG levels in CSF and Parkinson's disease.

Main Methods:

  • Developed a sandwich enzyme immunoassay (EIA) using purified beta 2-MG and a polyclonal antibody.
  • Measured beta 2-MG concentrations in CSF samples from Parkinson's disease patients and neurologically healthy controls.
  • Analyzed the correlation between beta 2-MG levels and DBH activity in CSF.

Related Experiment Videos

Main Results:

  • Established a reliable EIA for beta 2-MG quantification in CSF.
  • CSF beta 2-MG levels were significantly reduced in Parkinson's disease patients (0.63 +/- 0.09 microgram/ml) compared to controls (1.81 +/- 0.11 microgram/ml).
  • A strong positive correlation (r = 0.87) was found between CSF beta 2-MG content and DBH activity.

Conclusions:

  • Reduced beta 2-MG levels in CSF may serve as a potential biomarker for Parkinson's disease.
  • The findings suggest an interplay between immunological alterations and catecholaminergic neuron dysfunction in Parkinson's disease.
  • Further research is warranted to elucidate the precise role of beta 2-MG in the pathogenesis of Parkinson's disease.